Combination treatment for ultra-high-risk multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new combination of drugs for people newly diagnosed with a high-risk form of multiple myeloma. The goal is to see if this combination is safe and works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with multiple myeloma and have measurable disease.
- Your cancer is considered ultra-high-risk due to genetic changes, high numbers of plasma cells in the blood, or the presence of tumors outside the bone marrow.
- You have not received prior treatment for multiple myeloma, except for a short course of steroids for emergencies.
- You do not have severe nerve pain or other significant medical conditions that would make the trial unsafe.
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs for patients with newly diagnosed, high-risk multiple myeloma. The goal is to see if this multi-target approach can improve outcomes by using the immune system to attack the cancer.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This study tests a new drug called CM336 (a bispecific antibody) combined with standard care for people with high-risk multiple myeloma that came back quickly after first treatment. The goal is to see if it helps control the disease better.
This study tests a new treatment combination for people with high-risk multiple myeloma who are newly diagnosed and healthy enough for a stem cell transplant. The goal is to see if the treatment can improve outcomes compared to standard therapy.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.